Honoring MG Awareness Month
June marks Myasthenia Gravis (MG) Awareness Month, a time dedicated to amplifying voices, deepening understanding, and advancing care for those living with this rare neuromuscular disorder. That’s why this series brings together expert insights and the latest research to shed light on the complexities of MG.
Episodes 1-7 of 7
Symptom Control in gMG: Comparing Ravulizumab and Efgartigimod
NeuroFrontiersSymptom Control in gMG: Comparing Ravulizumab and Efgartigimod
How Diagnostic Delays in gMG Impact Disease Severity, Outcomes, and Quality of Life
NeuroFrontiersHow Diagnostic Delays in gMG Impact Disease Severity, Outcomes, and Quality of Life
Quality-of-Life Challenges in gMG Care: Navigating the Invisible Burden
NeuroFrontiersQuality-of-Life Challenges in gMG Care: Navigating the Invisible Burden
Debunking gMG Myths: Counseling Strategies That Change the Conversation
NeuroFrontiersDebunking gMG Myths: Counseling Strategies That Change the Conversation
Investigating Inebilizumab for Generalized Myasthenia Gravis: Results from MINT
NeuroFrontiersInvestigating Inebilizumab for Generalized Myasthenia Gravis: Results from MINT
Reducing the Burden of gMG with a Novel B-Cell Therapy
NeuroFrontiersReducing the Burden of gMG with a Novel B-Cell Therapy
- advertisement
Exploring IGF1R as a New Therapeutic Target in Myasthenia Gravis
NeuroFrontiersExploring IGF1R as a New Therapeutic Target in Myasthenia Gravis
